Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Combined company aims to be a leader in the field of tissue repair and regeneration Late-stage clinical pipeline of novel sealants and orthobiologics ...
Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Extraordinary Shareholders' Meeting....
Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has been dosed in a Phase 1 clinical trial with an...
Cytos Biotechnology Ltd (SIX:CYTN) today announced that Novartis will discontinue the NIC002 project, which is a therapeutic vaccine candidate for...
Cytos Biotechnology Ltd (SIX:CYTN) today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.